Electrodiagnostic Parameters After Sets Transfer in Patients With Ulnar Compression Neuropathy

Overview

About this study

The primary objective of the study is to determine the degree of axonal contribution from the transferred Anterior Interosseous Nerve (AIN) to the ulnar innervated intrinsic muscles of the hand after a Supercharged End to Side AIN to Ulnar Motor Nerve Transfer (SETS-AIN) in patients with severe ulnar compression neuropathy. The degree of axonal contribution will be determined by physical examination (grip strength, pinch strength, intrinsic muscle strength) and electrodiagnostic studies (nerve conduction studies and electromyography).

Secondary objectives include comparing the results of decompression (DCS) + SETS with patients undergoing DCS alone and DCS and end to end nerve transfers. Additional objectives include developing a new electrodiagnostic protocol for evaluating the degree of return of function after SETS transfer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Demographic characteristics (e.g. gender, age) and the health state, presence or absence of a medical condition/disease.
  • Required laboratory results, diagnostic methods, criteria for classification of current status, as measured within XX days prior to randomization. List specific tests and documentation methods.  
  • Prior therapy, if any.  Consider listing specific prior treatments.  Consider listing the allowable duration of prior therapy for the specific population to be studied (e.g., treatment-naïve, treatment-experienced or prior-treatment-failed “salvage” participants). 
  • Ability to understand study procedures and to comply with them for the entire length of the study.
  • If men and women of reproductive capability will be enrolled, indicate whether contraception is necessary and required. If yes, include details of allowable contraception methods for trial.

Exclusion Criteria: 

  • Specify health status or any clinical conditions (e.g., life expectancy, co-existing disease) or other characteristics that precludes appropriate diagnosis, treatment or follow-up in the trial.
  •  Clinical/laboratory indicators of current status, obtained within XX days prior to   randomization.  List the specific tests to be performed and the narrowest acceptable range of laboratory values for exclusion, consistent with disease and/or safety. Include as many as necessary. 
  • Specify any exclusion related to pregnancy, lactation, or plans to become pregnant. Specify methods for assessing current status and willingness to use contraception, if applicable. Include as many as necessary.
  • Use of [excluded drugs, behavioral interventions, devices, etc.] within XX days prior to study entry. Treatment with another investigational drug or intervention (with time frame).
  • For drug studies: allergy/sensitivity to study drugs or their ingredients.
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
  • Current or past participation within a specified timeframe in another clinical trial, as warranted by the administration of this intervention.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/27/2025. Questions regarding updates should be directed to the study team contact.
 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kitty Wu, M.D.

Open for enrollment

Contact information:

Amy Holst

(507) 266-4467

Holst.Amy@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20582614

Mayo Clinic Footer